[{"id":"9a9ff008-2d0b-4d26-91f5-d8f2ec4ab9cd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672251","created_at":"2023-01-05T14:58:29.816Z","updated_at":"2025-02-25T16:39:34.057Z","phase":"Phase 2","brief_title":"Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05672251","lead_sponsor":"City of Hope Medical Center","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 01/02/2024","start_date":" 01/02/2024","primary_txt":" Primary completion: 04/22/2025","primary_completion_date":" 04/22/2025","study_txt":" Completion: 04/22/2025","study_completion_date":" 04/22/2025","last_update_posted":"2025-02-06"},{"id":"e6bd139e-7d5b-486d-888f-481618f10fed","acronym":"LONCA","url":"https://clinicaltrials.gov/study/NCT05270057","created_at":"2022-03-08T16:52:28.981Z","updated_at":"2024-07-02T16:34:59.173Z","phase":"Phase 1","brief_title":"Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies","source_id_and_acronym":"NCT05270057 - LONCA","lead_sponsor":"Medical College of Wisconsin","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" MYC rearrangement • BCL6 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement • BCL6 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 01/26/2023","start_date":" 01/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-06-04"},{"id":"dd766908-e225-4f48-b3e4-5c4320450a92","acronym":"LOTIS 5","url":"https://clinicaltrials.gov/study/NCT04384484","created_at":"2021-01-18T21:10:09.473Z","updated_at":"2024-07-02T16:35:00.891Z","phase":"Phase 3","brief_title":"Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT04384484 - LOTIS 5","lead_sponsor":"ADC Therapeutics S.A.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Rituxan (rituximab) • oxaliplatin • Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2028","study_completion_date":" 06/30/2028","last_update_posted":"2024-05-27"},{"id":"0b1f1a53-7cb2-4d32-83e6-718629eb9a72","acronym":"","url":"https://clinicaltrials.gov/study/NCT04998669","created_at":"2021-08-10T14:52:57.364Z","updated_at":"2024-07-02T16:35:07.404Z","phase":"Phase 2","brief_title":"Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma","source_id_and_acronym":"NCT04998669","lead_sponsor":"Juan P. Alderuccio, MD","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Recruiting","enrollment":" Enrollment 39","initiation":"Initiation: 02/11/2022","start_date":" 02/11/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2027","study_completion_date":" 08/01/2027","last_update_posted":"2024-04-26"},{"id":"2e6e5e2d-1a57-4604-852d-212e232f5d2d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05971251","created_at":"2023-08-02T14:08:39.430Z","updated_at":"2024-07-02T16:35:24.878Z","phase":"Phase 1","brief_title":"Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia","source_id_and_acronym":"NCT05971251","lead_sponsor":"Mayur Narkhede","biomarkers":" CD20 • CD5 • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD5 • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Calquence (acalabrutinib) • Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 12/18/2023","start_date":" 12/18/2023","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2023-12-29"},{"id":"783e04f8-062b-4c34-babc-abe45daa957a","acronym":"FIL_COLUMN","url":"https://clinicaltrials.gov/study/NCT05249959","created_at":"2023-07-20T18:09:57.431Z","updated_at":"2024-07-02T16:35:25.841Z","phase":"Phase 2","brief_title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","source_id_and_acronym":"NCT05249959 - FIL_COLUMN","lead_sponsor":"Fondazione Italiana Linfomi - ETS","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cytarabine • bendamustine • Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 04/21/2022","start_date":" 04/21/2022","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2027","study_completion_date":" 02/01/2027","last_update_posted":"2023-12-19"},{"id":"cdc869cf-4cc9-4c85-b49c-627365f9e0ab","acronym":"","url":"https://clinicaltrials.gov/study/NCT05658562","created_at":"2022-12-20T14:58:53.320Z","updated_at":"2024-07-02T16:35:25.935Z","phase":"Phase 1/2","brief_title":"A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL","source_id_and_acronym":"NCT05658562","lead_sponsor":"Mitsubishi Tanabe Pharma Corporation","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Recruiting","enrollment":" Enrollment 49","initiation":"Initiation: 01/30/2023","start_date":" 01/30/2023","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 08/01/2028","study_completion_date":" 08/01/2028","last_update_posted":"2023-12-18"},{"id":"6a4eb48f-d80a-4473-8435-28c248997a37","acronym":"","url":"https://clinicaltrials.gov/study/NCT05222438","created_at":"2022-02-05T18:29:17.280Z","updated_at":"2024-07-02T16:35:30.883Z","phase":"Phase 2","brief_title":"Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant","source_id_and_acronym":"NCT05222438","lead_sponsor":"Barbara Ann Karmanos Cancer Institute","biomarkers":" MYC • BCL2 • CD19 • BCL6","pipe":" | ","alterations":" CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["MYC • BCL2 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 positive • BCL2 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/08/2022","start_date":" 04/08/2022","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-11-01"},{"id":"d2f039be-9031-413c-b2c1-18e8d9c8043b","acronym":"LOTIS-2","url":"https://clinicaltrials.gov/study/NCT03589469","created_at":"2021-01-18T17:39:09.365Z","updated_at":"2024-07-02T16:35:38.806Z","phase":"Phase 2","brief_title":"Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT03589469 - LOTIS-2","lead_sponsor":"ADC Therapeutics S.A.","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zynlonta (loncastuximab tesirine-lpyl)"],"overall_status":"Completed","enrollment":" Enrollment 145","initiation":"Initiation: 08/01/2018","start_date":" 08/01/2018","primary_txt":" Primary completion: 05/24/2020","primary_completion_date":" 05/24/2020","study_txt":" Completion: 08/09/2022","study_completion_date":" 08/09/2022","last_update_posted":"2023-08-29"},{"id":"9e7a575f-c788-4036-96b5-6c3613c1655d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05600686","created_at":"2022-10-31T13:57:06.475Z","updated_at":"2024-07-02T16:35:46.258Z","phase":"Phase 2","brief_title":"Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma","source_id_and_acronym":"NCT05600686","lead_sponsor":"Joseph Tuscano","biomarkers":" BCL2 • BCL6 • CD4","pipe":" | ","alterations":" BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • BCL6 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • Zynlonta (loncastuximab tesirine-lpyl) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 05/24/2023","start_date":" 05/24/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 02/01/2028","study_completion_date":" 02/01/2028","last_update_posted":"2023-06-07"},{"id":"13917bc1-f69e-4f24-b014-53e056a50078","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228249","created_at":"2022-02-12T17:47:56.603Z","updated_at":"2024-07-02T16:35:57.657Z","phase":"Phase 1","brief_title":"Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT05228249","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" BCL2 • BCL6","pipe":"","alterations":" ","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • etoposide IV • carmustine • melphalan • Zynlonta (loncastuximab tesirine-lpyl) • Starasid (cytarabine ocfosfate)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2023-01-13"},{"id":"f1b173cf-5e6a-4243-a2dc-cddb4fa79a72","acronym":"","url":"https://clinicaltrials.gov/study/NCT02370160","created_at":"2021-01-18T11:17:26.599Z","updated_at":"2024-07-02T16:36:51.390Z","phase":"Phase 1/2","brief_title":"HM2014-26 DT2219 for Relapsed or Refractory B-Lineage Leukemia or Lymphoma","source_id_and_acronym":"NCT02370160","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OXS-1550"],"overall_status":"Completed","enrollment":" Enrollment 18","initiation":"Initiation: 12/21/2015","start_date":" 12/21/2015","primary_txt":" Primary completion: 04/08/2018","primary_completion_date":" 04/08/2018","study_txt":" Completion: 04/08/2018","study_completion_date":" 04/08/2018","last_update_posted":"2020-01-13"},{"id":"9b0e7bf4-bb20-480b-bb6a-5b8c166fdc23","acronym":"STARLYTE","url":"https://clinicaltrials.gov/study/NCT01472887","created_at":"2021-01-18T06:08:34.898Z","updated_at":"2024-07-02T16:37:14.503Z","phase":"Phase 2","brief_title":"SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients","source_id_and_acronym":"NCT01472887 - STARLYTE","lead_sponsor":"Sanofi","biomarkers":" CD19","pipe":" | ","alterations":" CD19 expression","tags":["CD19"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e coltuximab ravtansine (SAR3419)"],"overall_status":"Completed","enrollment":" Enrollment 61","initiation":"Initiation: 01/01/2012","start_date":" 01/01/2012","primary_txt":" Primary completion: 09/01/2016","primary_completion_date":" 09/01/2016","study_txt":" Completion: 09/01/2016","study_completion_date":" 09/01/2016","last_update_posted":"2018-01-25"},{"id":"5e8b88b8-ff47-433a-a99e-7a4b183ba806","acronym":"","url":"https://clinicaltrials.gov/study/NCT00889408","created_at":"2021-01-18T03:24:18.974Z","updated_at":"2024-07-02T16:37:15.928Z","phase":"Phase 1","brief_title":"DT2219ARL for Relapsed or Refractory CD19 (+), CD 22 (+) B-Lineage Leukemia Or Lymphoma","source_id_and_acronym":"NCT00889408","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" CD22","pipe":"","alterations":" ","tags":["CD22"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e OXS-1550"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 12/02/2013","start_date":" 12/02/2013","primary_txt":" Primary completion: 07/21/2014","primary_completion_date":" 07/21/2014","study_txt":" Completion: 07/21/2014","study_completion_date":" 07/21/2014","last_update_posted":"2017-12-02"}]